BridgeMD
New treatment option for Severe Hypertriglyceridemia
Official title A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
ClinicalTrials.gov ID: NCT07269210
What this study is testing
What is Solbinsiran?
Solbinsiran is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for severe hypertriglyceridemia.
Also referred to as LY3561774.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
- Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
- Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
You likely can't join if
- Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
- Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
- Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral...
- Have a history of chronic alcohol abuse within 3 years prior to screening
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- Beverly Hills, California, United States
- Long Beach, California, United States
- Montclair, California, United States
- Northridge, California, United States
- Hamden, Connecticut, United States
- Jacksonville, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- Winter Park, Florida, United States
- Chicago, Illinois, United States
- Brownsburg, Indiana, United States
- Covington, Kentucky, United States
- Bowie, Maryland, United States
- Worcester, Massachusetts, United States
- Las Vegas, Nevada, United States
- Pennington, New Jersey, United States
- New York, New York, United States
- Houston, Texas, United States
+ 19 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States; Tucson, Arizona, United States; Beverly Hills, California, United States; Long Beach, California, United States; Montclair, California, United States; Northridge, California, United States and 33 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.